Ideal Patient to Receive Alimata Plus Keytruda: KEYNOTE-189

Ideal Patient to Receive Alimata Plus Keytruda: KEYNOTE-189

obr

4 months
116 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope explains the ideal patient to receive Alimta plus Keytrude based on data and results from KEYNOTE-189.
Up Next Autoplay
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Category: Kidney Cancer
1,151 Views
obr 4 months
Most Anticipated Trial Results Regarding Biomarkers in RCC
Most Anticipated Trial Results Regarding Biomarkers in RCC
Category: Kidney Cancer
416 Views
obr 4 months
Strategies for Treating RCC in the 2nd Line Setting
Strategies for Treating RCC in the 2nd Line Setting
Category: Kidney Cancer
270 Views
obr 4 months
Perspective on Treating Newly Diagnosed RCC Patients
Perspective on Treating Newly Diagnosed RCC Patients
Category: Kidney Cancer
286 Views
obr 4 months
Studies in Sarcomatoid RCC and Urothelial Cancer
Studies in Sarcomatoid RCC and Urothelial Cancer
Category: Kidney Cancer
220 Views
obr 4 months
PDIGREE Trial in Metastatic Untreated RCC
PDIGREE Trial in Metastatic Untreated RCC
Category: Kidney Cancer
130 Views
obr 4 months
Smoldering MM Presented at ASCO 2019
Smoldering MM Presented at ASCO 2019
Category: Multiple Myeloma
179 Views
obr 4 months
MAIA Study Outcomes
MAIA Study Outcomes
Category: Multiple Myeloma
276 Views
obr 4 months
IV Daratumumab versus Subcutaneous Daratumumab
IV Daratumumab versus Subcutaneous Daratumumab
Category: Acute Lymphoblastic Leukemia
114 Views
obr 4 months
SOPHIA Trial in HER+ Metastatic Breast Cancer
SOPHIA Trial in HER+ Metastatic Breast Cancer
Category: Acute Lymphoblastic Leukemia
136 Views
obr 4 months